制药公司Beeringer Ingelheim和Tessellate生物合作伙伴开发癌症治疗方法,治疗难以治疗的肿瘤。 Pharmaceuticals Boehringer Ingelheim and Tessellate Bio partner to develop cancer treatments for hard-to-treat tumors.

Boehringer Ingelheim和Tessellate Bio合作开发新的癌症治疗方法,针对依赖替代的调子长长的肿瘤(ALT),10-15%的预测力差的癌症就呈现了这一特征。 Boehringer Ingelheim and Tessellate Bio have partnered to develop new cancer treatments targeting tumors that rely on alternative lengthening of telomeres (ALT), a feature present in 10-15% of cancers with poor prognoses. 合作的目的是制作口服精密疗法,交易价值超过5亿欧元。 The collaboration aims to produce oral precision therapies and has a deal value exceeding €500 million. 这一伙伴关系支持Boehringer Ingelheim改善癌症治疗和扩大肿瘤研究的承诺。 This partnership supports Boehringer Ingelheim's commitment to improving cancer treatments and expands their oncology research.